vs
Side-by-side financial comparison of BRANDYWINE REALTY TRUST (BDN) and Esperion Therapeutics, Inc. (ESPR). Click either name above to swap in a different company.
Esperion Therapeutics, Inc. is the larger business by last-quarter revenue ($168.4M vs $127.0M, roughly 1.3× BRANDYWINE REALTY TRUST). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs 4.5%). Over the past eight quarters, Esperion Therapeutics, Inc.'s revenue compounded faster (10.6% CAGR vs 0.7%).
Brandywine Realty Trust is a Philadelphia-based real estate investment trust (REIT) that invests in office buildings in Philadelphia, Washington, D.C., and Austin, Texas.
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
BDN vs ESPR — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $127.0M | $168.4M |
| Net Profit | $-48.8M | — |
| Gross Margin | — | — |
| Operating Margin | 1.2% | 50.6% |
| Net Margin | -38.4% | — |
| Revenue YoY | 4.5% | 143.7% |
| Net Profit YoY | -80.4% | — |
| EPS (diluted) | $-0.28 | $0.32 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $127.0M | — | ||
| Q4 25 | $121.0M | $168.4M | ||
| Q3 25 | $121.4M | $87.3M | ||
| Q2 25 | $120.6M | $82.4M | ||
| Q1 25 | $121.5M | $65.0M | ||
| Q4 24 | $121.9M | $69.1M | ||
| Q3 24 | $131.8M | $51.6M | ||
| Q2 24 | $125.3M | $73.8M |
| Q1 26 | $-48.8M | — | ||
| Q4 25 | $-36.7M | — | ||
| Q3 25 | $-25.9M | $-31.3M | ||
| Q2 25 | $-88.7M | $-12.7M | ||
| Q1 25 | $-27.0M | $-40.5M | ||
| Q4 24 | $-44.5M | — | ||
| Q3 24 | $-165.2M | $-29.5M | ||
| Q2 24 | $30.2M | $-61.9M |
| Q1 26 | — | — | ||
| Q4 25 | 61.3% | — | ||
| Q3 25 | 62.6% | — | ||
| Q2 25 | 62.4% | — | ||
| Q1 25 | 60.8% | — | ||
| Q4 24 | 61.2% | — | ||
| Q3 24 | 64.9% | — | ||
| Q2 24 | 63.1% | — |
| Q1 26 | 1.2% | — | ||
| Q4 25 | 22.8% | 50.6% | ||
| Q3 25 | 20.8% | -11.4% | ||
| Q2 25 | -34.3% | 8.6% | ||
| Q1 25 | 12.5% | -34.0% | ||
| Q4 24 | 18.0% | -6.4% | ||
| Q3 24 | -7.2% | -31.0% | ||
| Q2 24 | 15.5% | 3.5% |
| Q1 26 | -38.4% | — | ||
| Q4 25 | -30.3% | — | ||
| Q3 25 | -21.3% | -35.9% | ||
| Q2 25 | -73.5% | -15.4% | ||
| Q1 25 | -22.2% | -62.2% | ||
| Q4 24 | -36.5% | — | ||
| Q3 24 | -125.4% | -57.2% | ||
| Q2 24 | 24.1% | -83.9% |
| Q1 26 | $-0.28 | — | ||
| Q4 25 | $-0.21 | $0.32 | ||
| Q3 25 | $-0.15 | $-0.16 | ||
| Q2 25 | $-0.51 | $-0.06 | ||
| Q1 25 | $-0.16 | $-0.21 | ||
| Q4 24 | $-0.25 | $-0.14 | ||
| Q3 24 | $-0.96 | $-0.15 | ||
| Q2 24 | $0.17 | $-0.33 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $36.2M | $167.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | — | $-302.0M |
| Total Assets | $3.6B | $465.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $36.2M | — | ||
| Q4 25 | $32.3M | $167.9M | ||
| Q3 25 | $75.5M | $92.4M | ||
| Q2 25 | $122.6M | $86.1M | ||
| Q1 25 | $29.4M | $114.6M | ||
| Q4 24 | $90.2M | $144.8M | ||
| Q3 24 | $36.5M | $144.7M | ||
| Q2 24 | $30.4M | $189.3M |
| Q1 26 | — | — | ||
| Q4 25 | $2.6B | — | ||
| Q3 25 | $2.3B | — | ||
| Q2 25 | $2.3B | — | ||
| Q1 25 | $2.2B | — | ||
| Q4 24 | $2.2B | — | ||
| Q3 24 | $2.3B | — | ||
| Q2 24 | $2.2B | — |
| Q1 26 | — | — | ||
| Q4 25 | $792.7M | $-302.0M | ||
| Q3 25 | $841.5M | $-451.4M | ||
| Q2 25 | $879.8M | $-433.5M | ||
| Q1 25 | $993.6M | $-426.2M | ||
| Q4 24 | $1.0B | $-388.7M | ||
| Q3 24 | $1.1B | $-370.2M | ||
| Q2 24 | $1.3B | $-344.2M |
| Q1 26 | $3.6B | — | ||
| Q4 25 | $3.6B | $465.9M | ||
| Q3 25 | $3.3B | $364.0M | ||
| Q2 25 | $3.4B | $347.1M | ||
| Q1 25 | $3.4B | $324.0M | ||
| Q4 24 | $3.5B | $343.8M | ||
| Q3 24 | $3.6B | $314.1M | ||
| Q2 24 | $3.8B | $352.3M |
| Q1 26 | — | — | ||
| Q4 25 | 3.23× | — | ||
| Q3 25 | 2.70× | — | ||
| Q2 25 | 2.63× | — | ||
| Q1 25 | 2.23× | — | ||
| Q4 24 | 2.13× | — | ||
| Q3 24 | 2.06× | — | ||
| Q2 24 | 1.73× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $45.2M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $116.7M | $45.2M | ||
| Q3 25 | $47.5M | $-4.3M | ||
| Q2 25 | $34.4M | $-31.4M | ||
| Q1 25 | $6.3M | $-22.6M | ||
| Q4 24 | $181.1M | $-35.0M | ||
| Q3 24 | $52.2M | $-35.3M | ||
| Q2 24 | $48.2M | $-7.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-35.5M | ||
| Q2 24 | — | $-7.3M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -68.7% | ||
| Q2 24 | — | -9.9% |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.0% | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | 0.0% | ||
| Q1 25 | — | 0.0% | ||
| Q4 24 | — | 0.0% | ||
| Q3 24 | — | 0.3% | ||
| Q2 24 | — | 0.1% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 1.60× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BDN
| Rents | $120.7M | 95% |
| Third party management fees, labor reimbursement and leasing | $4.7M | 4% |
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
